{
  "docId": "019de072-7781-7512-96cc-a2b05ce755c7",
  "docSlug": "b1746432eb5f270eac90273cddb862aa",
  "documentTitle": "Bionomics | Investor Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 38,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide outlines a 12-week outpatient BID dosing period followed by a follow-up phase, with specific primary and secondary endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-7781-7512-96cc-a2b05ce755c7/19",
  "deckHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7",
  "deckJsonHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7.json",
  "deckAnchorHref": "/decks/019de072-7781-7512-96cc-a2b05ce755c7#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.3,
        "y": 0.075
      },
      "kind": "callout",
      "text": "Fast Track designation from FDA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b042be84-f131-4e31-99f2-39848a050776",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.32,
        "x": 0.66,
        "y": 0.075
      },
      "kind": "callout",
      "text": "Topline data expected 1H'23",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcee8a77-db32-447f-a077-69d7a7b880d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.15,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "12-week study timeline with outpatient BID dosing and follow-up",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7c82c30-cb9b-4672-8d14-8845757ca660",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.25,
        "y": 0.045
      },
      "kind": "list",
      "text": "SECONDARY ENDPOINTS: Various patient-reported symptoms of PTSD, changes in anxiety and depression symptoms, and global and social functioning; Safety & tolerability endpoints. PRIMARY ENDPOINT: Investigator-rated PTSD symptoms on CAPS-5 Total Symptom Severity Scores in change from Baseline to Week 12 compared to placebo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf8dbc96-8066-4221-97b2-c18afdd91487",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.05,
        "y": 0.025
      },
      "kind": "paragraph",
      "text": "Phase 2b 1:1 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED BNC210 MONOTHERAPY IN PTSD PATIENTS ~200 Subjects",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c09ec9c-08bc-4a8d-b9c8-51e79870901c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.13,
        "y": 0.088
      },
      "kind": "source-note",
      "text": "BID = Twice daily dosing; CAPS-5 = Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd68057a-17de-49e9-bfa5-738978f93e23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.73,
        "y": 0.012
      },
      "kind": "table",
      "text": "PHASE 2b: Single potential registrational-supporting trial for monotherapy treatment in PTSD. KEY INCLUSION CRITERIA: Female and male (18 – 75 years), Current PTSD diagnosis, CAPS-5 ≥ 30, ~25 Sites",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e089be11-47dc-43ee-868a-00ecafc592eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.03
      },
      "kind": "title",
      "text": "BNC210 Phase 2b PTSD ATTUNE Study Underway",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7a0da9e-31c4-4b15-b465-9c2d1bd878ad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "0240f094-0ea3-4d4f-88ac-1383d276ddca",
      "evidence": "Timeline visualization of clinical trial phases",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}